Ovarian cancer cohort( OvCa+ FT+ PP) :
193/298 patients (65%
of the
overall study population)
•
All pts had received prior platinum chemotherapy.
•
Eligibility criteria: Platinum Resistant or ”no suitable for further
platinum therapy”( toxicity or hypersensitive reactions)
•
77% gBRCA 1
•
23% gBRCA 2
•
Mean previous lines of QT:4.4( 1-14)
Olaparib monotherapy: 400mg/12h until PD and/or unacceptable toxicity.
Treatment well tolerated, although 3 patients treated for 6-10m died
(2acute leukaemia, 1 MDS)
Kaufman B et al; J Clin Oncol 2015; Jan 20;33(3): 244-50
“Protocol 42”
